Brigham and Women's Hospital, United States
Disclosure information not submitted.
The risk of cardiovascular (CV) events after initiation of SGLT2i, GLP-1RA, DPP4i, or SUs in patients with T2D and low-to-moderate CV risk
Wednesday, August 28, 20249:00 AM – 9:15 AM CEST
